Expression of P‑gp in acute myeloid leukemia and the reversal function of As2O3 on drug resistance

Gao,Feng; Dong,Wanwei; Yang,Wei; Liu,Jia; Zheng,Zhihong; Sun,Kailai

doi:10.3892/ol.2014.2692

Expression of P‑gp in acute myeloid leukemia and the reversal function of As2O3 on drug resistance

Authors:
- Feng Gao
- Wanwei Dong
- Wei Yang
- Jia Liu
- Zhihong Zheng
- Kailai Sun
View Affiliations

Affiliations: Department of Genetics, China Medical University, Shenyang, Liaoning 110001, P.R. China, Laboratory Animal Center, China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: November 10, 2014 https://doi.org/10.3892/ol.2014.2692
Pages: 177-182

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To study the expression of P‑glycoprotein (P‑gp) and the reversal function of As2O3, the active ingredient of arsenic, on drug resistance in acute myeloid leukemia (AML) patients, P‑gp and cluster of differentiation 34 (CD34) were examined in primary mononuclear and resistant cells, with or without As2O3. In addition, multidrug resistance gene 1 (MDR1) mRNA expression was investigated in K562/D cells and AML patients. In total, 28.6% of newly‑treated (NT) patients and 59.1% of relapsed/refractory (RR) patients were P‑gpfunction+, and 31.7% of NT patients and 59.1% of RR patients were CD34+. The positivity rate of P‑gpfunction and CD34+ expression in the RR group were significantly higher compared with that in the NT group (P<0.05). In addition, higher CD34+, P‑gpexpression+ and P‑gpfunction+ values were observed in older patients compared with younger patients. MDR1 expression was downregulated in certain patients following treatment with AS2O3. In the present study, the overexpression of P‑gp was the primary cause of drug resistance in the AML patients, and MDR1 expression was downregulated by As2O3 in primary leukemia and drug‑resistant cells.

View Figures

View References

1	Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 10:159–165. 2003.PubMed/NCBI
2	Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK and Willman CL: Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR⁻/efflux⁺ and MDR1⁺/efflux⁻ cases. Blood. 86:2329–2342. 1995.PubMed/NCBI
3	Gao FZM, Liu Y and Sun K: Analyses of expression and function of P-glycoprotein in relapsed/refractory acute myelogenous leukemia patients. Journal of Leukemia & Lymphoma. 15:419–421. 2006.(In Chinese).
4	Huls M, Russel FG and Masereeuw R: The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther. 328:3–9. 2009. View Article : Google Scholar
5	Mahadevan D and List AF: Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 104:1940–1951. 2004. View Article : Google Scholar : PubMed/NCBI
6	Lopes EC, Scolnik M, Alvarez E and Hajos SE: Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells. Leuk Res. 25:85–93. 2001. View Article : Google Scholar : PubMed/NCBI
7	Malmo J, Sandvig A, Vårum KM and Strand SP: Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach. PLoS One. 8:e541822013. View Article : Google Scholar : PubMed/NCBI
8	Aliabadi HM, Mahdipoor P and Uludağ H: Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells. Cancer Gene Ther. 20:169–77. 2013. View Article : Google Scholar : PubMed/NCBI
9	Haase D, Feuring-Buske M, Könemann S, Fonatsch C, Troff C, Verbeek W, Pekrun A, Hiddemann W and Wörmann B: Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood. 86:2906–2912. 1995.PubMed/NCBI
10	Feller N, Schuurhuis GJ, van der Pol MA, Westra G, Weijers GW, van Stijn A, Huijgens PC and Ossenkoppele GJ: High percentage of CD34 positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia. 17:68–75. 2003. View Article : Google Scholar : PubMed/NCBI
11	Samdani A, Vijapurkar U, Grimm MA, Spier CS, Grogan TM, Glinsmann-Gibson BJ and List AF: Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res. 20:175–180. 1996. View Article : Google Scholar : PubMed/NCBI
12	Zhu J, Chen Z, Lallemand-Breitenbach V and de Thé H: How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2:705–713. 2002. View Article : Google Scholar : PubMed/NCBI
13	Sun HD, Ma L, Hu XC and Zhang TD: Ai-ling 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Trad Chin West Med. 12:21992.(In Chinese).
14	Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, et al: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia: As₂O₃ induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061. 1996.PubMed/NCBI
15	Zhang PWS, Hu LH, Shi FD, Qiu FQ, Hong GJ, Han XY, Yang HF, Sun YZ, Liu YP, Zhao J and Jin ZJ: Treatment of 72 cases of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin J Hematol. 5:41996.(In Chinese).
16	Chen Z, Wang ZY and Chen SJ: Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther. 76:141–149. 1997. View Article : Google Scholar
17	Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, et al: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): I. As₂O₃ exerts dose-dependent dual effects on APL cells. Blood. 89:3345–3353. 1997.PubMed/NCBI
18	Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, et al: Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 328:240–243. 2010. View Article : Google Scholar : PubMed/NCBI
19	Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, Qi Q, Lu N, Tao L, Wang XT, et al: Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett. 279:13–21. 2009. View Article : Google Scholar : PubMed/NCBI
20	Zhao YFJ, Liang J, Chen B, Yao R, Shang Q and Wang S: MDR reversing and apoptosis inducing effects on treatment with arsenic trioxide in gastric cancer cell cine SGC7901/ADM. Clin Oncol Cancer Res. 32:32005.(In Chinese).
21	Fuss IJ, Kanof ME, Smith PD and Zola H: Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol. Chapter 7:2000.
22	Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
23	Abd El-Ghaffar HA, Aladle DA, Farahat SE and Abd El-Hady N: P-glycoprotein (P-170) expression in acute leukemias. Hematology. 11:35–41. 2006. View Article : Google Scholar : PubMed/NCBI
24	Li X, Li J, Du W, Zhang J, Liu W, Chen X, Li H, Huang S and Li X: Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia. APMIS. 119:76–84. 2011. View Article : Google Scholar
25	Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS, Wu X, Zhou WH, Huang RW and Liu Q: Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med. 9:712011. View Article : Google Scholar : PubMed/NCBI
26	Oelschlaegel U, Mohr B, Schaich M, Schäkel U, Kroschinsky F, Illmer T, Ehninger G and Thiede C: HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. Cytometry B Clin Cytom. 76:321–327. 2009. View Article : Google Scholar : PubMed/NCBI
27	Gao FLY, Hou K and Sun K: The relationship between age of AML patients and expression of P-gp. Chin J Prac Int Med. 27:22007.(In Chinese).
28	Xue YW, Han JG, Li BX and Yang BF: Reversal effect and mechanism of arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901. Yao Xue Xue Bao. 42:949–953. 2007.(In Chinese). PubMed/NCBI
29	Wang T, Ma LM, Zhang HP, Wang HW, Yang LH and Qiao ZH: The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms. Zhonghua Xue Ye Xue Za Zhi. 28:438–443. 2007.(In Chinese). PubMed/NCBI
30	Yang C and Lui S: The clinical significance of overexpression of drug-resistance genes and reversal of multidrug resistance in cancer. Bulletin of Chinese Cancer. 10:132–136. 2001.(In Chinese).
31	Praet M, Stryckmans P and Ruysschaert JM: Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells. Biochem Pharmacol. 51:1341–1348. 1996. View Article : Google Scholar : PubMed/NCBI